45P Rare and non-canonical ALK fusion in advanced NSCLC: Heterogeneous clinical outcomes with ALK inhibitors
Year: 2026
Type: article
Abstract: ALK rearrangements define a clinically relevant subset of non-small cell lung cancer (NSCLC) sensitive to ALK tyrosine kinase inhibitors (TKIs). While EML4–ALK is the most frequent fusion, next-generation sequencing (NGS) has enabled the identification of rare ALK fusion partners, whose clinical behavior and outcomes with ALK-targeted therapies remain poorly characterized in routine clinical practice.
Source: ESMO Open
Authors: S. Intagliata, N. Bianchi, G. Ghirardi, M. Cardisperi, D. Morotti, A.C. Bettini, S. Pala, P.C. Scolari, L. Bonomi, L. Ghilardi, C. Moro, C. Milani, A. Zambelli
Institutions: Ospedale Papa Giovanni XXIII, University of Milano-Bicocca
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7138185740
FWCI:
Cites:
Cited by:
Related to: